Volume 31, Number 3—March 2025
Dispatch
National Active Case-Finding Program for Tuberculosis in Prisons, Peru, 2024
Table 2
Predictive value of CAD4TB, symptom screening, and sputum testing among participants in a national active case-finding program for TB in prisons, Peru, 2024*
CAD4TB score | Symptoms | No. (%) | Sputum collected | TB confirmed |
||
---|---|---|---|---|---|---|
No. confirmed | % TB cases (95% CI)† | % Sputum positivity (95% CI)‡ | ||||
<40 | ||||||
N | 30,335 (78.3) | 333 | 17 | 1.6 (0.9–2.5) | 5.1 (3.0–8.1) | |
Y |
2,491 (6.4) |
1,250 |
85 |
7.8 (6.3–9.6) |
6.8 (5.5–8.3) |
|
≥40 | ||||||
N | 3,786 (9.8) | 3,642 | 445 | 40.9 (37.9–43.9) | 12.2 (11.2–13.3) | |
Y |
2,122 (5.5) |
2,066 |
542 |
49.8 (46.8–52.8) |
26.2 (24.4–28.2) |
|
Total | 38,734 | 7,291 | 1,089 |
*CAD4TB, Computer-Aided Detection for Tuberculosis version 7.0 (Delft Imaging Systems, https://delft.care); TB, tuberculosis. †TB case defined as any positive or trace result via Xpert MTB/RIF Ultra (Cepheid, https://www.cepheid). ‡Sputum positivity calculated as percentage of individuals with sputum collected who are confirmed to have TB via Xpert MTB/RIF Ultra (Cepheid).
1These senior authors contributed equally to this article.